Patents by Inventor Karla Drescher

Karla Drescher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES
    Publication number: 20200283439
    Abstract: The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.
    Type: Application
    Filed: October 14, 2019
    Publication date: September 10, 2020
    Inventors: Hannes Koolman, Wilfried Braje, Helmut Mack, Andreas Haupt, Ana Lucia Relo, Karla Drescher, Margaretha Henrica Maria Bakker, Viktor Lakics, Carolin Hoft, Ruxu Xu, Xiaona Zhao
  • PROLINE AMIDE COMPOUNDS AND THEIR AZETIDINE ANALOGUES CARRYING A SPECIFICALLY SUBSTITUTED BENZYL RADICAL
    Publication number: 20200039930
    Abstract: The present invention relates to proline amide compounds and their azetidine derivatives of formula I wherein the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, to a method for preventing or treating conditions and disorders which respond to the modulation of the 5-HT2C receptor, and processes for preparing such compounds and compositions.
    Type: Application
    Filed: March 20, 2018
    Publication date: February 6, 2020
    Inventors: Gisela Backfisch, Margaretha Henrica Maria Bakker, Lawrence Black, Wilfried Braje, Karla Drescher, Thomas Erhard, Andreas Haupt, Carolin Hoft, Andreas Kling, Viktor Lakics, Helmut Mack, Frank Oellien, Ana Lucia Relo
  • HEXAHYDROPYRAZINOBENZ- OR -PYRIDO-OXAZEPINES CARRYING AN OXYGEN-CONTAINING SUBSTITUENT AND USE THEREOF IN THE TREATMENT OF 5-HT2C-DEPENDENT DISORDERS
    Publication number: 20200002354
    Abstract: The present invention relates to compound of formula (I) wherein the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, to their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.
    Type: Application
    Filed: September 3, 2019
    Publication date: January 2, 2020
    Inventors: Gisela Backfisch, Margaretha Henrica Maria Bakker, Günter Blaich, Wilfried Braje, Karla Drescher, Thomas Erhard, Andreas Haupt, Carolin Hoft, Viktor Lakics, Helmut Mack, Frank Oellien, Raimund Peter, Ana Lucia Relo
  • Inhibitor compounds of phosphodiesterase type 10A
    Patent number: 10308610
    Abstract: The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: June 4, 2019
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.
    Inventors: Hervé Geneste, Michael Ochse, Karla Drescher, Jürgen Dinges, Clarissa Jakob
  • TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES
    Publication number: 20190071443
    Abstract: The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.
    Type: Application
    Filed: November 2, 2018
    Publication date: March 7, 2019
    Inventors: Hannes Koolman, Wilfried Braje, Helmut Mack, Andreas Haupt, Ana Lucia Relo, Karla Drescher, Margaretha Henrica Maria Bakker, Viktor Lakics, Carolin Hoft, Ruxu Xu, Xiaona Zhao
  • PYRIDYL OR PYRAZINYL COMPOUNDS CARRYING A METHYL-BOUND ALPHA-AMINO ACID AMIDE GROUP
    Publication number: 20190062305
    Abstract: The present invention relates to pyridyl or pyrazinyl compounds carrying a methyl-bound N-amide moiety derived from an ?-amino acid of formula I where the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, and to their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of the 5-HT2C receptor.
    Type: Application
    Filed: September 21, 2016
    Publication date: February 28, 2019
    Inventors: Gisela BACKFISCH, Margaretha BAKKER, Günter BLAICH, Wilfried BRAJE, Karla DRESCHER, Thomas ERHARD, Andreas HAUPT, Carolin HOFT, Andreas KLING, Viktor LAKICS, Helmut MACK, Frank OELLIEN, Raimund PETER, Frauke POHLKI, Ana Lucia RELO
  • TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES
    Publication number: 20190048007
    Abstract: The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.
    Type: Application
    Filed: June 8, 2018
    Publication date: February 14, 2019
    Inventors: Hannes Koolman, Wilfried Braje, Helmut Mack, Andreas Haupt, Ana Lucia Relo, Karla Drescher, Margaretha Henrica Maria Bakker, Viktor Lakics, Carolin Hoft
  • HEXAHYDROPYRAZINOBENZ- OR -PYRIDO-OXAZEPINES CARRYING AN OXYGEN-CONTAINING SUBSTITUENT AND USE THEREOF IN THE TREATMENT OF 5-HT2C-DEPENDENT DISORDERS
    Publication number: 20180339996
    Abstract: The present invention relates to compound of formula (I) (I) wherein the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, to their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.
    Type: Application
    Filed: November 24, 2016
    Publication date: November 29, 2018
    Inventors: Gisela BACKFISCH, Margaretha Henrica Maria BAKKER, Günter BLAICH, Wilfried BRAJE, Karla DRESCHER, Thomas ERHARD, Andreas HAUPT, Carolin HOFT, Viktor LAKICS, Helmut MACK, Frank OELLIEN, Raimund PETER, Ana Lucia RELO
  • Tricyclic quinoline and quinoxaline derivatives
    Patent number: 10118926
    Abstract: The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: November 6, 2018
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.
    Inventors: Hannes Koolman, Wilfried Braje, Helmut Mack, Andreas Haupt, Ana Lucia Relo, Karla Drescher, Margaretha Henrica Maria Bakker, Viktor Lakics, Carolin Hoft, Ruxu Xu, Xiaona Zhao
  • NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
    Publication number: 20180222905
    Abstract: The present invention relates to novel carboxamide compounds, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating or controlling medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Application
    Filed: April 9, 2018
    Publication date: August 9, 2018
    Inventors: Hervé Geneste, Michael Ochse, Karla Drescher, Berthold Behl, Loic Laplanche, Jürgen Dinges, Clarissa Jakob, Katja Jantos
  • Tricyclic quinoline and quinoxaline derivatives
    Patent number: 9994568
    Abstract: The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: June 12, 2018
    Assignee: ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Hannes Koolman, Wilfried Braje, Helmut Mack, Andreas Haupt, Ana Lucia Relo, Karla Drescher, Margaretha Henrica Maria Bakker, Viktor Lakics, Carolin Hoft
  • NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
    Publication number: 20180099936
    Abstract: The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Application
    Filed: December 13, 2017
    Publication date: April 12, 2018
    Inventors: Hervé Geneste, Michael Ochse, Karla Drescher, Jürgen Dinges, Clarissa Jakob
  • Inhibitor compounds of phosphodiesterase type 10A
    Patent number: 9938269
    Abstract: The present invention relates to novel carboxamide compounds, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating or controlling medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Grant
    Filed: June 27, 2012
    Date of Patent: April 10, 2018
    Assignees: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO KG
    Inventors: Hervé Geneste, Michael Ochse, Karla Drescher, Berthold Behl, Loic Laplanche, Jürgen Dinges, Clarissa Jakob, Katja Jantos
  • NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
    Publication number: 20180030033
    Abstract: The present invention relates to compounds of the formula I and their salts etc. which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Application
    Filed: October 4, 2017
    Publication date: February 1, 2018
    Inventors: Hervé GENESTE, Sean Colm TURNER, Michael OCHSE, Karla DRESCHER, Lawrence A. BLACK, Katja JANTOS
  • Inhibitor compounds of phosphodiesterase type 10A
    Patent number: 9856220
    Abstract: The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: January 2, 2018
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Hervé Geneste, Michael Ochse, Karla Drescher, Jürgen Dinges, Clarissa Jakob
  • Inhibitor compounds of phosphodiesterase type 10A
    Patent number: 9790203
    Abstract: The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: October 17, 2017
    Assignees: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Hervé Geneste, Sean Colm Turner, Michael Ochse, Karla Drescher, Lawrence A. Black, Katja Jantos
  • HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL
    Publication number: 20170158693
    Abstract: The present invention relates to tricyclic hexahydrodiazepinoquinolines carrying a cyclic substituent, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor, and processes for preparing such compounds and compositions.
    Type: Application
    Filed: February 17, 2017
    Publication date: June 8, 2017
    Inventors: Gisela BACKFISCH, Margaretha Henrica Maria BAKKER, Günter BLAICH, Wilfried BRAJE, Karla DRESCHER, Thomas ERHARD, Andreas HAUPT, Hannes KOOLMAN, Viktor LAKICS, Anna LINSENMEIER, Helmut MACK, Raimund PETER, Ana Lucia RELO, Xiaona ZHAO, Jincheng WANG
  • Substituted furo[3,2-c]pyridines, thieno[3,2-c]pyridines, thieno[2,3-d]pyridazines and pyrido[3,4-d]pyridazines as phosphodiesterase type 10A inhibitors
    Patent number: 9657034
    Abstract: The present invention relates to novel compounds of the formula I which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Grant
    Filed: January 18, 2016
    Date of Patent: May 23, 2017
    Assignees: AbbVie Deuschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Hervé Geneste, Michael Ochse, Karla Drescher, Sean Turner, Berthold Behl, Loic Laplanche, Jürgen Dinges, Clarissa Jakob, Lawrence Black, Katja Jantos
  • HEXAHYDRODIAZEPINOQUINOLINES CARRYING A SUBSTITUTED ALKYL RADICAL
    Publication number: 20170112851
    Abstract: The present invention relates to tricyclic hexahydrodiazepinoquinolines carrying a substituted alkyl radical, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor, and processes for preparing such compounds and compositions.
    Type: Application
    Filed: January 4, 2017
    Publication date: April 27, 2017
    Inventors: Gisela BACKFISCH, Margaretha Henrica Maria BAKKER, Günter BLAICH, Wilfried BRAJE, Karla DRESCHER, Thomas ERHARD, Andreas HAUPT, Viktor LAKICS, Anna LINSENMEIER, Helmut MACK, Raimund PETER, Ana Lucia RELO, Lynette SMITH
  • Substituted [1,4]diazepino[6,7,1-ij]quinolines as serotonin 5-HT2C receptor modulators
    Patent number: 9573950
    Abstract: The present invention relates to compound of formula (I) as tricyclic hexahydrodiazepinoquinolines carrying a cyclic substituent, useful for modulating the 5-HT2C receptor and preventing and/or treating conditions and disorders that respond to the modulation of the 5-HT2C receptor. The present invention also relates to methods for producing compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for preventing or treating conditions and disorders that respond to the modulation of the 5-HT2C receptor by administering compounds of formula (1) or pharmaceutical compositions thereof.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: February 21, 2017
    Assignee: AbbVie Deutschland GmbH & Co KG
    Inventors: Gisela Backfisch, Margaretha Henrica Maria Bakker, Günter Blaich, Wilfried Braje, Karla Drescher, Thomas Erhard, Andreas Haupt, Hannes Koolman, Viktor Lakics, Anna Linsenmeier, Helmut Mack, Raimund Peter, Ana Lucia Relo, Xiaona Zhao, Jincheng Wang